Towards physico-relevant dissolution testing: The importance of solid-state analysis in dissolution

Dissolution Technologies

Volumn 16, Issue 2, 2009, Pages 47-54

  Aaltonen, Jaakko ^a,b   Rades, Thomas ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 69349100378     PISSN: 1521298X     EISSN: None     Source Type: Journal    
DOI: 10.14227/DT160209P47     Document Type: Note

References (20)

1. Hilfiker, R. Polymorphism in the Pharmaceutical Industry; WILEY-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2006.
2. Amidon, G. L.; Lennernäs, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: The correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995, 12, 413-420.
3. Pudipeddi, M.; Serajuddin, A. T. M. Trends in solubility of polymorphs. J. Pharm. Sci, 2005, 94, 929-939.
4. Hancock, B. C.; Parks, M. What is the true solubility advantage for amorphous pharmaceuticals? Pharm. Res. 2000, 17, 397-404.
5. Bauer, J.; Spanton, S.; Henry, R.; Quick, J.; Dziki, W.; Porter, W.; Morris, J. Ritonavir: an extraordinary example of conformational polymorphism. Pharm. Res. 2001, 18 (6), 859-866.
6. Cardew, P. T.; Davey, R. J.; Ruddick, A. J. Kinetics of polymorphic solid-state transformations. J. Chem. Soc., Faraday Trans. 2 1984, 80, 659-668.
7. Cardew, P. T.; Davey, R. J. The kinetics of solvent-mediated phase transformations. Proc. R. Soc. London, Ser. A 1985, 398, 415-428.
8. Stagner, W. C.; Guillory, J. K. Physical characterization of solid iopanoic acid forms. J. Pharm. Sci. 1979, 68, 1005-1009.
9. Shefter, E.; Higuchi, T. Dissolution behavior of crystalline solvated and nonsolvated forms of some pharmaceuticals. J. Pharm. Sci. 1963, 52, 781-791.
10. Kahela, P.; Aaltonen, R.; Lewing, E.; Anttila, M.; Kristoffersson, E. Pharmacokinetics and dissolution of two crystalline forms of carbamazepine. Int. J. Pharm. 1983, 14, 103-112.
11. Laihanen, N.; Muttonen, E.; Laaksonen, M. Solubility and intrinsic dissolution rate of alprazolam crystal modifications. Pharm. Dev. Technol. 1996, 1, 373-380.
12. Meyer, M. C.; Straughn, A. B.; Jarvi, E. J.; Wood, G. C.; Pelsor, F. R.; Shah, V. P. The bioinequivalence of carbamazepine tablets with a history of clinical failures. Pharm. Res. 1992, 9, 1612-1616.
13. Ibrahim, H. G.; Pisano, F.; Bruno, A. Polymorphism of phenylbutazone-properties and compressional behavior of crystals. J. Pharm. Sci. 1977, 66, 669-673.
14. Galia, E.; Nicolaides, E.; Hörter, D.; Löbenberg, R.; Reppas, C.; Dressman, J. B. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998,15, 698-705.
15. Schöll, J.; Bonalumi, D.; Vicum, L.; Mazzotti, M.; Muller, M. In situ monitoring and modeling of the solvent-mediated polymorphic transformation of L-glutamic acid. Cryst. Growth Des. 2006, 6 (4), 881-891.
16. Lu, X.; Lozano, R.; Shah, P. In Situ Dissolution Testing using Different UV Fiber Optic Probes and Instruments. Dissolution Technol. 2003, 10 (4), 6-15.
17. Aaltonen, J.; Heinänen, P.; Peltonen, L.; Kortejärvi, H.; Tanninen, V. P.; Christiansen, L.; Hirvonen, J.; Yliruusi, J.; Rantanen, J. In situ measurement of solvent-mediated phase transformations during dissolution testing. J. Pharm. Sci. 2006, 95 (12), 2730-2737.
18. Savolainen, M.; Kogermann, K.; Heinz, A.; Aaltonen, J.; Peltonen, L.; Strachan, C.; Yliruusi, J. Better understanding of dissolution behaviour of amorphous drugs by in situ solid-state analysis using Raman spectroscopy. Eur. J. Pharm. Biopharm. 2009, 71 (1), 71-79.
19. Tian, F.; Sandler, N.; Aaltonen, J.; Lang, C.; Saville, D. J.; Gordon, K. C.; Strachan, C. J.; Rantanen, J.; Rades, T. Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts. J. Pharm. Sci. 2007, 96 (3), 584-594.
20. Lehto, P.; Aaltonen, J.; Tenho, M.; Rantanen, J.; Hirvonen, J.; Tanninen, V. P.; Peltonen, L. Solvent-mediated solid phase transformations of carbamazepine-Effects of Simulated Intestinal Fluid and Fasted State Simulated Intestinal Fluid. J. Pharm. Sci. 2009, 98, 985-996.